Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04935021

Clinical Study of ATTR-CM

In this study, patients with ATTR-CM or gene carriers were selected to study the diagnosis and treatment, and long-term follow-up was conducted.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Transthyroxine Amyloidosis Cardiomyopathy

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

xiaohong University PAN

Hangzhou, Zhejiang, China

Location status: Recruiting

Location contact

xiaohong U PAN

CONTACT

+8613857116993

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients and gene carriers of ATTR-CM confirmed in the Second Affiliated Hospital of Zhejiang University School of Medicine, regardless of gender, age 18-90 years old;
  • Patients who have the ability to understand the test and can cooperate with investigators

Exclusion criteria

  • Patients who unable to understand or unwilling to fill in informed consent forms or follow visitors

Treatment and study plan

ATTR-CM

Drug

Current treatment

Primary outcomes

  1. Rate of cardiovascular death, myocardial infarction, and stroke

    Time frame: 10 year

    Primary Outcome

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Other

Registry information

Official study title

Clinical Study Protocol of Transthyroxine Protein Amyloidosis Cardiomyopathy and Its Gene Carriers

Important dates

Study start
2021
Primary completion
2031
Study completion
2031
First posted
Jun 22, 2021
Registry last updated
Jan 31, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.